Neurocrine Biosciences Company Profile (NASDAQ:NBIX)

About Neurocrine Biosciences

Neurocrine Biosciences logoNeurocrine Biosciences, Inc. is engaged in the development of pharmaceutical products focused on neurological and endocrine-based diseases and disorders. The Company's two lead late-stage clinical programs are Elagolix, a gonadotropin-releasing hormone (GnRH) antagonist for women's health that is partnered with AbbVie Inc. (AbbVie), and NBI-98854 (valbenazine), a vesicular monoamine transporter 2 (VMAT2) inhibitor for the treatment of movement disorders. The Company focuses on developing NBI-640756 against Essential tremor. Its research and development focuses on addressing diseases and disorders of the central nervous and endocrine systems, which include therapeutic categories ranging from hypothalamic-pituitary-adrenal (HPA) disorders to stress-related disorders and neurological/neuropsychiatric diseases. Its Corticotropin-Releasing Factor (CRF) is a hypothalamic hormone released directly into the hypophyseal portal vasculature.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Drugs - Generic
  • Sub-Industry: Biotechnology
  • Exchange: NASDAQ
  • Symbol: NBIX
  • CUSIP: 64125C10
Key Metrics:
  • Previous Close: $43.08
  • 50 Day Moving Average: $42.27
  • 200 Day Moving Average: $45.89
  • 52-Week Range: $87,114,000.00 - $32.18
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -32.86
  • P/E Growth: 0.51
  • Market Cap: $3.72B
  • Outstanding Shares: 87,114,000
  • Beta: 0.55
  • Return on Equity: -32.04%
  • Return on Assets: -28.53%
  • Current Ratio: 13.42%
  • Quick Ratio: 13.42%
Additional Links:
Companies Related to Neurocrine Biosciences:

Analyst Ratings

Consensus Ratings for Neurocrine Biosciences (NASDAQ:NBIX) (?)
Ratings Breakdown: 1 Hold Rating, 14 Buy Ratings
Consensus Rating:Buy (Score: 2.93)
Consensus Price Target: $67.23 (57.38% upside)

Analysts' Ratings History for Neurocrine Biosciences (NASDAQ:NBIX)
DateFirmActionRatingPrice TargetDetails
2/16/2017Needham & Company LLCReiterated RatingBuy$62.00View Rating Details
2/16/2017HC WainwrightBoost Price TargetPositive$80.00 -> $100.00View Rating Details
2/15/2017Cowen and CompanyReiterated RatingBuyView Rating Details
2/15/2017Robert W. BairdReiterated RatingOutperform$66.00View Rating Details
2/14/2017Oppenheimer Holdings, Inc.Set Price TargetBuy$60.00View Rating Details
2/10/2017ICAPReiterated RatingOutperform$55.00View Rating Details
2/10/2017Piper Jaffray CompaniesReiterated RatingOverweight$96.00View Rating Details
2/9/2017Leerink SwannReiterated RatingOutperform$65.00View Rating Details
1/27/2017CIBCUpgradeMarket Perform -> OutperformView Rating Details
1/19/2017Deutsche Bank AGReiterated RatingBuy$65.00 -> $62.00View Rating Details
1/19/2017BMO Capital MarketsReiterated RatingOutperform$72.00View Rating Details
1/18/2017Jefferies Group LLCLower Price TargetBuy$61.00 -> $56.00View Rating Details
11/22/2016Citigroup Inc.Initiated CoverageMarket Perform$55.00View Rating Details
11/3/2016Barclays PLCReiterated RatingBuy$60.00View Rating Details
5/4/2016J P Morgan Chase & CoReiterated RatingBuyView Rating Details
11/2/2015NomuraBoost Price TargetBuy$34.00 -> $43.00View Rating Details
(Data available from 2/26/2015 forward)


Earnings History for Neurocrine Biosciences (NASDAQ:NBIX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/14/2017Q416($0.56)($0.51)$4.55 millionViewListenView Earnings Details
11/2/2016Q316($0.57)($0.43)ViewN/AView Earnings Details
5/5/2016Q1($0.29)($0.22)$15.43 million$15.00 millionViewN/AView Earnings Details
2/11/2016Q415($0.32)($0.34)$3.33 millionViewListenView Earnings Details
10/29/2015Q315($0.25)($0.40)$6.66 millionViewListenView Earnings Details
7/29/2015Q2($0.29)($0.28)$0.41 millionViewListenView Earnings Details
4/30/2015Q115($0.30)($0.01)$19.76 millionViewN/AView Earnings Details
2/9/2015Q414($0.24)($0.26)ViewN/AView Earnings Details
11/3/2014Q314($0.21)($0.21)ViewN/AView Earnings Details
8/6/2014Q214($0.18)($0.18)$0.12 millionViewN/AView Earnings Details
4/30/2014Q114($0.19)($0.17)ViewN/AView Earnings Details
2/6/2014Q413($0.17)($0.16)$0.79 million$0.73 millionViewN/AView Earnings Details
10/29/2013Q313($0.20)($0.17)$0.79 million$0.73 millionViewN/AView Earnings Details
7/25/2013Q2 2013($0.20)($0.18)$0.77 million$0.73 millionViewListenView Earnings Details
5/2/2013Q1 2013($0.18)($0.18)$1.07 million$0.70 millionViewListenView Earnings Details
2/8/2013Q4 2012($0.08)$0.14$9.43 million$21.90 millionViewListenView Earnings Details
10/31/2012Q312($0.05)($0.05)$10.28 million$9.40 millionViewN/AView Earnings Details
7/31/2012($0.03)($0.01)ViewN/AView Earnings Details
5/2/2012($0.01)ViewN/AView Earnings Details
10/31/2011$0.19$0.56ViewN/AView Earnings Details
7/28/2011$0.04$0.04ViewN/AView Earnings Details
5/3/2011$0.05$0.05ViewN/AView Earnings Details
2/10/2011$0.04$0.05ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Neurocrine Biosciences (NASDAQ:NBIX)
Current Year EPS Consensus Estimate: $-2.34 EPS
Next Year EPS Consensus Estimate: $-1.30 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20162($0.26)($0.25)($0.26)
Q2 20162($0.52)($0.47)($0.50)
Q3 20162($0.56)($0.53)($0.55)
Q4 20164($0.62)($0.53)($0.57)
Q1 20174($0.88)($0.54)($0.64)
Q2 20174($0.65)($0.56)($0.60)
Q3 20174($0.73)($0.28)($0.49)
Q4 20174($0.65)($0.24)($0.44)
(Data provided by Zacks Investment Research)


Dividend History for Neurocrine Biosciences (NASDAQ:NBIX)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading History for Neurocrine Biosciences (NASDAQ:NBIX)
Insider Ownership Percentage: 4.80%
Institutional Ownership Percentage: 97.60%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
2/7/2017Malcolm Lloyd-SmithInsiderSell116$44.61$5,174.76View SEC Filing  
2/6/2017Dimitri E GrigoriadisInsiderSell727$43.13$31,355.51View SEC Filing  
2/6/2017Kevin Charles GormanCEOSell3,010$43.18$129,971.80View SEC Filing  
2/6/2017Timothy P CoughlinCFOSell963$43.14$41,543.82View SEC Filing  
2/3/2017Christopher Flint ObrienInsiderSell1,500$42.50$63,750.00View SEC Filing  
2/3/2017Kevin Charles GormanCEOSell3,125$42.55$132,968.75View SEC Filing  
2/1/2017William H RastetterDirectorSell10,750$42.28$454,510.00View SEC Filing  
1/17/2017Haig P BozigianInsiderSell1,625$40.63$66,023.75View SEC Filing  
1/17/2017Kevin Charles GormanCEOSell3,750$40.65$152,437.50View SEC Filing  
1/17/2017Timothy P CoughlinCFOSell1,750$40.65$71,137.50View SEC Filing  
1/10/2017Christopher Flint ObrienInsiderSell1,750$43.35$75,862.50View SEC Filing  
1/10/2017Kevin Charles GormanCEOSell3,750$43.28$162,300.00View SEC Filing  
11/15/2016Christopher Flint ObrienInsiderSell25,000$52.84$1,321,000.00View SEC Filing  
9/1/2016Malcolm Lloyd-SmithInsiderSell9,000$50.00$450,000.00View SEC Filing  
8/15/2016Christopher Flint ObrienInsiderSell12,500$48.73$609,125.00View SEC Filing  
8/8/2016Corinne H NevinnyDirectorSell5,000$48.54$242,700.00View SEC Filing  
5/25/2016Richard F PopsDirectorSell15,000$46.72$700,800.00View SEC Filing  
5/16/2016Christopher Flint ObrienInsiderSell25,000$45.00$1,125,000.00View SEC Filing  
4/11/2016Kyle GanoInsiderSell41,770$44.02$1,838,715.40View SEC Filing  
4/6/2016Christopher Flint ObrienInsiderSell25,000$45.00$1,125,000.00View SEC Filing  
2/3/2016Haig P BozigianInsiderSell1,375$38.13$52,428.75View SEC Filing  
2/3/2016Kevin Charles GormanCEOSell3,125$38.04$118,875.00View SEC Filing  
2/3/2016Timothy P CoughlinCFOSell1,500$38.06$57,090.00View SEC Filing  
1/19/2016Haig P BozigianInsiderSell1,625$46.77$76,001.25View SEC Filing  
1/19/2016Kevin Charles GormanCEOSell3,750$46.70$175,125.00View SEC Filing  
1/19/2016Timothy P CoughlinCFOSell1,750$46.69$81,707.50View SEC Filing  
1/11/2016Haig P BozigianInsiderSell1,625$44.25$71,906.25View SEC Filing  
1/11/2016Kevin Charles GormanCEOSell3,750$44.17$165,637.50View SEC Filing  
1/11/2016Timothy P CoughlinCFOSell1,750$44.25$77,437.50View SEC Filing  
11/27/2015Dimitri E. GrigoriadisinsiderSell10,000$57.50$575,000.00View SEC Filing  
11/9/2015Darin LippoldtinsiderSell23,761$52.92$1,257,432.12View SEC Filing  
10/16/2015Haig P BozigianInsiderSell25,000$47.78$1,194,500.00View SEC Filing  
10/16/2015Kevin Charles GormanCEOSell33,500$47.77$1,600,295.00View SEC Filing  
9/18/2015Gary A. LyonsDirectorSell15,000$54.89$823,350.00View SEC Filing  
7/20/2015Dimitri E GrigoriadisInsiderSell19,646$55.00$1,080,530.00View SEC Filing  
7/20/2015Timothy P CoughlinCFOSell20,000$55.00$1,100,000.00View SEC Filing  
7/13/2015Dimitri E GrigoriadisInsiderSell10,000$50.00$500,000.00View SEC Filing  
7/13/2015Timothy P CoughlinCFOSell20,000$50.00$1,000,000.00View SEC Filing  
6/23/2015W Thomas MitchellDirectorSell15,000$49.35$740,250.00View SEC Filing  
6/8/2015Christopher Flint ObrienInsiderSell10,000$45.00$450,000.00View SEC Filing  
6/8/2015Timothy P CoughlinCFOSell60,000$45.08$2,704,800.00View SEC Filing  
3/24/2015Gary A LyonsDirectorSell30,000$41.53$1,245,900.00View SEC Filing  
3/24/2015Kevin Charles GormanCEOSell40,000$41.53$1,661,200.00View SEC Filing  
2/10/2015Dimitri E GrigoriadisInsiderSell20,000$35.00$700,000.00View SEC Filing  
1/16/2015Christopher Flint ObrienInsiderSell1,750$30.79$53,882.50View SEC Filing  
1/16/2015Kevin Charles GormanCEOSell3,750$30.79$115,462.50View SEC Filing  
1/12/2015Kevin Charles GormanCEOSell3,750$28.43$106,612.50View SEC Filing  
1/12/2015Kyle GanoInsiderSell1,250$28.41$35,512.50View SEC Filing  
1/12/2015Timothy P CoughlinCFOSell1,750$28.37$49,647.50View SEC Filing  
1/8/2015Dimitri E GrigoriadisInsiderSell30,000$27.35$820,500.00View SEC Filing  
1/8/2015Kevin Charles GormanCEOSell25,000$27.39$684,750.00View SEC Filing  
1/8/2015Timothy P CoughlinCFOSell10,000$27.25$272,500.00View SEC Filing  
1/5/2015Dimitri E GrigoriadisInsiderSell2,500$22.76$56,900.00View SEC Filing  
1/2/2015W Thomas MitchellDirectorSell8,000$22.79$182,320.00View SEC Filing  
12/19/2014Christopher Flint ObrienInsiderSell20,000$24.02$480,400.00View SEC Filing  
12/19/2014Kevin Charles GormanCEOSell70,000$23.41$1,638,700.00View SEC Filing  
12/19/2014Timothy P CoughlinCFOSell30,000$23.46$703,800.00View SEC Filing  
12/17/2014Kyle GanoInsiderSell4,957$22.50$111,532.50View SEC Filing  
12/15/2014Dimitri E GrigoriadisInsiderSell12,794$22.35$285,945.90View SEC Filing  
12/12/2014Kyle GanoInsiderSell4,043$22.50$90,967.50View SEC Filing  
12/11/2014Christopher Flint ObrienInsiderSell40,000$21.82$872,800.00View SEC Filing  
12/10/2014Timothy P CoughlinCFOSell20,000$21.48$429,600.00View SEC Filing  
12/10/2014W Thomas MitchellDirectorSell7,000$21.90$153,300.00View SEC Filing  
11/28/2014Timothy P CoughlinCFOSell10,000$20.14$201,400.00View SEC Filing  
11/24/2014Christopher Flint ObrienInsiderSell5,463$19.53$106,692.39View SEC Filing  
10/31/2014Timothy P CoughlinCFOSell10,000$19.00$190,000.00View SEC Filing  
10/30/2014Timothy P CoughlinCFOSell20,000$18.31$366,200.00View SEC Filing  
10/1/2014W Thomas MitchellDirectorSell1,275$15.50$19,762.50View SEC Filing  
9/15/2014Gary A LyonsDirectorSell20,000$15.66$313,200.00View SEC Filing  
1/17/2014Dimitri GrigoriadisInsiderSell25,000$20.00$500,000.00View SEC Filing  
1/10/2014Christopher Flint ObrienInsiderSell6,750$18.88$127,440.00View SEC Filing  
1/10/2014Kevin Charles GormanCEOSell3,750$18.57$69,637.50View SEC Filing  
1/10/2014Timothy CoughlinCFOSell1,750$18.56$32,480.00View SEC Filing  
1/7/2014Dimitri GrigoriadisInsiderSell25,000$17.50$437,500.00View SEC Filing  
1/7/2014Kevin Charles GormanCEOSell108,000$16.76$1,810,080.00View SEC Filing  
1/7/2014Timothy CoughlinCFOSell70,000$16.75$1,172,500.00View SEC Filing  
9/4/2013Kyle GanoInsiderSell2,400$15.61$37,464.00View SEC Filing  
9/3/2013Christopher Flint ObrienInsiderSell5,000$16.00$80,000.00View SEC Filing  
8/21/2013Haig BozigianInsiderSell13,999$15.04$210,544.96View SEC Filing  
8/21/2013Timothy CoughlinCFOSell19,035$15.05$286,476.75View SEC Filing  
8/6/2013W Thomas MitchellDirectorSell1,531$14.70$22,505.70View SEC Filing  
8/5/2013Haig BozigianInsiderSell11,001$15.00$165,015.00View SEC Filing  
8/5/2013Timothy CoughlinCFOSell10,965$14.99$164,365.35View SEC Filing  
7/12/2013Christopher Flint ObrienInsiderSell5,000$14.50$72,500.00View SEC Filing  
6/28/2013Christopher Flint ObrienInsiderSell11,357$13.33$151,388.81View SEC Filing  
6/27/2013Haig P BozigianInsiderSell8,000$13.00$104,000.00View SEC Filing  
6/21/2013Dimitri E GrigoriadisInsiderSell46,837$12.51$585,930.87View SEC Filing  
(Data available from 1/1/2013 forward)


Latest Headlines for Neurocrine Biosciences (NASDAQ:NBIX)
News IconTracking the Metrics on Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) - Providence Standard (NASDAQ:NBIX) - February 25 at 2:17 AM
News IconWhat are the Technical Charts Saying About Neurocrine Biosciences Inc (NBIX) - BVN (NASDAQ:NBIX) - February 25 at 2:17 AM
News IconAre Analysts Optimistic About Where Neurocrine Biosciences, Inc. (NASDAQ:NBIX) is Heading? - Winfield Review (NASDAQ:NBIX) - February 23 at 8:36 AM
News IconEPS Of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) At $-0.61 - Stock Observer (NASDAQ:NBIX) - February 23 at 8:36 AM
News IconInteresting NBIX Put And Call Options For April 21st (NASDAQ:NBIX) - February 23 at 12:38 AM
News IconStock Review for Neurocrine Biosciences, Inc. (NASDAQ:NBIX) - The Standard (NASDAQ:NBIX) - February 22 at 6:51 PM
News IconAnalysts Peer Into Their Crystal Balls For Neurocrine Biosciences, Inc. (NASDAQ:NBIX): Where Is It headed? - Winfield Review (NASDAQ:NBIX) - February 21 at 6:07 PM
News IconStreet Recommendation Roundup on Xencor, Inc. (NASDAQ:XNCR ... - Rockville Register (NASDAQ:NBIX) - February 20 at 6:07 PM logoNEUROCRINE BIOSCIENCES INC Financials (NASDAQ:NBIX) - February 18 at 5:57 PM
News IconNeurocrine Biosciences Inc (NASDAQ:NBIX) Stock Technicals Hit Weakness (NASDAQ:NBIX) - February 17 at 5:09 PM logoNeurocrine Biosciences : Reports Year-End 2016 Results and Provides Investor Update for 2017 (NASDAQ:NBIX) - February 17 at 5:09 PM logoNEUROCRINE BIOSCIENCES, INC. (NASDAQ:NBIX) Files An 8-K Results of Operations and Financial Condition (NASDAQ:NBIX) - February 17 at 5:09 PM logoNeurocrine Biosciences Building Toward Bigger Things - Seeking Alpha (NASDAQ:NBIX) - February 16 at 6:20 PM logoNBIX: Acquires North American Rights to ONGENTYS® For the Treatment of Parkinson’s Disease (NASDAQ:NBIX) - February 16 at 6:20 PM logoNeurocrine Biosciences, Inc. :NBIX-US: Earnings Analysis: 2016 By the Numbers : February 16, 2017 (NASDAQ:NBIX) - February 16 at 6:20 PM logoEARNINGS SUMMARY: Details of Neurocrine Biosciences Inc Q4 Earnings Report (NASDAQ:NBIX) - February 14 at 9:21 PM logoNeurocrine Biosciences : and BIAL Announce Exclusive North American Licensing Agreement for Opicapone (NASDAQ:NBIX) - February 14 at 9:21 PM logoQ4 2016 Neurocrine Biosciences Inc Earnings Release - After Market Close (NASDAQ:NBIX) - February 14 at 9:21 PM logoNeurocrine Biosciences Reports Year-End 2016 Results and Provides Investor Update for 2017 (NASDAQ:NBIX) - February 14 at 9:21 PM logoNeurocrine reports 4Q loss (NASDAQ:NBIX) - February 14 at 9:21 PM logoNEUROCRINE BIOSCIENCES INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements an (NASDAQ:NBIX) - February 14 at 9:21 PM
News IconThe Neurocrine Biosciences, Inc. (NBIX) Insider Sells $31355.51 in Stock (NASDAQ:NBIX) - February 14 at 12:58 AM logoNEUROCRINE BIOSCIENCES, INC. (NASDAQ:NBIX) Files An 8-K Entry into a Material Definitive Agreement (NASDAQ:NBIX) - February 12 at 6:40 PM logoNeurocrine Inks $145M Parkinson's Drug Deal (NBIX) (NASDAQ:NBIX) - February 10 at 7:41 PM logoNeurocrine Inks $145 Million Parkinson's Drug Deal (NASDAQ:NBIX) - February 10 at 7:41 PM logoNEUROCRINE BIOSCIENCES INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Change in Directors or Pri (NASDAQ:NBIX) - February 10 at 7:41 PM
News IconBIAL Announce Exclusive North American Licensing Agreement for Opicapone (NASDAQ:NBIX) - February 10 at 5:51 AM logoNeurocrine Biosciences (NBIX), Bail Enter Pact for Opicapone (NASDAQ:NBIX) - February 10 at 5:51 AM logoNeurocrine Biosciences (NBIX), Bail Enter Pact for Opicapone - (NASDAQ:NBIX) - February 9 at 7:48 PM logoNeurocrine and BIAL Announce Exclusive North American Licensing Agreement for Opicapone (NASDAQ:NBIX) - February 9 at 7:48 PM logoNeurocrine Biosciences Announces Conference Call and Webcast to Report Fourth Quarter and Year-End 2016 Results - PR Newswire (press release) (NASDAQ:NBIX) - February 7 at 3:22 PM logoNeurocrine Biosciences Announces Conference Call and Webcast to Report Fourth Quarter and Year-End 2016 Results (NASDAQ:NBIX) - February 7 at 3:22 PM logoThe Positive Investment Case For Neurocrine Biosciences - Seeking Alpha (NASDAQ:NBIX) - February 4 at 5:36 AM logoNeurocrine Biosciences, Inc. breached its 50 day moving average in a Bullish Manner : NBIX-US : February 1, 2017 (NASDAQ:NBIX) - February 1 at 7:51 PM
News IconNeurocrine Biosciences Inc NBIX Pharmaceuticals Healthcare Deals and Alliances Profile Prices from USD $250 (NASDAQ:NBIX) - January 29 at 8:04 AM logoNeurocrine Biosci upgraded by Oppenheimer (NASDAQ:NBIX) - January 28 at 2:25 AM
News IconSorting Out the Technicals on Shares of Neurocrine Biosciences Inc. (NBIX) - Springdale Times (NASDAQ:NBIX) - January 25 at 8:21 PM
News IconEarnings in Full Force, Analysts Take Aim at Neurocrine Biosciences, Inc. (NASDAQ:NBIX) - Wall Street Beacon (NASDAQ:NBIX) - January 25 at 8:21 PM
News IconNews Impact Score Of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) At 79 - Stock Observer (NASDAQ:NBIX) - January 24 at 7:37 AM
News IconShares in Focus Neurocrine Biosciences Inc. (NBIX) - Sherwood Daily (NASDAQ:NBIX) - January 21 at 6:33 PM
News IconHealthcare Stock Review: Neurocrine Biosciences, Inc.'s (NBIX) (NASDAQ:NBIX) - January 20 at 7:33 PM
News IconRobert W. Baird Reiterates "Outperform" Rating for Neurocrine Biosciences Inc. (NBIX) (NASDAQ:NBIX) - January 20 at 7:33 PM
News IconNeurocrine Biosciences, Inc. (NBIX) Earns Outperform Rating from Robert W. Baird (NASDAQ:NBIX) - January 19 at 10:45 PM logoNBIX: Phase 2 Study of INGREZZA™ in Adults with Tourette Syndrome Fails to Hit Primary Endpoint (NASDAQ:NBIX) - January 19 at 10:45 PM
News IconChristopher Flint Obrien Sells 1750 Shares of Neurocrine Biosciences, Inc. (NBIX) Stock (NASDAQ:NBIX) - January 19 at 12:23 AM
News IconResearch Analysis of Neurocrine Biosciences Inc. (NASDAQ:NBIX) (NASDAQ:NBIX) - January 18 at 7:22 PM
News IconNeurocrine Biosciences Inc. (NASDAQ:NBIX) Stock current Trends Analysis (NASDAQ:NBIX) - January 18 at 7:22 PM logoNeurocrine Biosciences (NBIX) Reports Results from Phase II Clinical Study of VMAT2 Inhibitor INGREZZA - (NASDAQ:NBIX) - January 18 at 7:37 AM logo4:01 pm Neurocrine Biosci announces the top-line results from the Company's Phase II T-Forward study of INGREZZA (valbenazine) (NASDAQ:NBIX) - January 18 at 12:05 AM logoNeurocrine Biosciences (NBIX) Reports Results from Phase II Clinical Study of VMAT2 Inhibitor INGREZZA (NASDAQ:NBIX) - January 17 at 7:04 PM


What is Neurocrine Biosciences' stock symbol?

Neurocrine Biosciences trades on the NASDAQ under the ticker symbol "NBIX."

Where is Neurocrine Biosciences' stock going? Where will Neurocrine Biosciences' stock price be in 2017?

15 brokerages have issued twelve-month target prices for Neurocrine Biosciences' shares. Their predictions range from $55.00 to $100.00. On average, they expect Neurocrine Biosciences' stock price to reach $67.23 in the next year.

When will Neurocrine Biosciences announce their earnings?

Neurocrine Biosciences is scheduled to release their next quarterly earnings announcement on Wednesday, May, 3rd 2017.

What are analysts saying about Neurocrine Biosciences stock?

Here are some recent quotes from research analysts about Neurocrine Biosciences stock:

  • Cowen and Company analysts commented, "NBIX remains well funded, ending Q4 with $352MM in cash." (2/15/2017)

  • Robert W. Baird analysts commented, "No change to outlook heading into Ingrezza approval. Neurocrine reported a solid end to the year, modestly beating estimates on lower-than-expected opex. Though we are only a few weeks into 2017, it has already been a busy year for NBIX. Expect the year to continue to bring multiple updates, from potential approval of Ingrezza in TD and Tourette data in May to Phase 3 UF data for elagolix near year-end, an elagolix NDA submission, advances in CAH and essential tremor, and FDA discussions on newly licensed opicapone' Earnings and spend in-line, expect accelerations into launch. 4Q16 EPS of ($0.51) modestly beat our/consensus estimates of ($0.54)/($0.57), respectively, due to lower than projected operating expenses. Looking ahead to 2017, management expects opex to increase to about $230M-$240M due activities surrounding the launch of Ingrezza." (2/15/2017)
  • Needham & Company LLC analysts commented, "Company continues to prepare for Ingrezza launch ahead of 4/11/17 PDUFA date. We expect approval based on strength of Phase 3 data, followed by launch ~6wks later. We believe Boxed Warning/ REMS are possible. Phase 2 pediatric Tourette Syndrome (TS) data are expected May 2017 (was Apr). Given efficacy trend observed in adult Phase 2 TS, we believe Ingrezza will likely be active in pediatric TS as well. Elagolix NDA submission for Endometriosis by Abbvie is expected 3Q17 (was 2H17), triggering a $30M payment to Neurocrine. Phase 3 results in Uterine Fibroids are expected by YE17. We believe stock is attractive ahead of near term events. BUY." (2/10/2017)
  • HC Wainwright analysts commented, "We expect FDA to agree in early 2017 that Atara has demonstrated comparability between clinical batches of ATA-129, or EBV-CTL, and the prior material produced at MSKCC, paving the way for Phase 3 start. We believe comparability data will include the number of cells to administer, cytoreactivity, cell storage time, restriction studies (HLA types), variability based on release criteria, and the methods by which data are collected. CMC amendment standard for new clinical material Importantly, a CMC amendment is standard practice for an IND when new clinical material is introduced; therefore, we view Atara’s process as normal." (1/18/2017)

  • Jefferies Group LLC analysts commented, "While the study showed a stat sig improvement on the Clinical Global Impression of Change scale (CGI; p=0.015), the study did not reach stat sig on the 1EP of Yale Global Tic Severity Scale (YGTSS; p=0.18). No further trial details were released. Although a setback, we note that this does not directly read through to the pediatric study readout expected in April." (1/18/2017)

Who owns Neurocrine Biosciences stock?

Neurocrine Biosciences' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include FMR LLC (14.91%), Perceptive Advisors LLC (3.82%), Franklin Resources Inc. (2.77%), Janus Capital Management LLC (2.71%), State Street Corp (2.64%) and Orbimed Advisors LLC (2.45%). Company insiders that own Neurocrine Biosciences stock include Christopher Flint Obrien, Corinne H Nevinny, Darin Lippoldt, Dimitri E Grigoriadis, Gary A Lyons, Haig P Bozigian, Kevin Charles Gorman, Kyle Gano, Malcolm Lloyd-Smith, Richard F Pops, Timothy P Coughlin, W Thomas Mitchell and William H Rastetter.

Who sold Neurocrine Biosciences stock? Who is selling Neurocrine Biosciences stock?

Neurocrine Biosciences' stock was sold by a variety of institutional investors in the last quarter, including Asset Management One Co. Ltd., AQR Capital Management LLC, FMR LLC, Guggenheim Capital LLC, GRT Capital Partners L.L.C., Allianz Asset Management AG, RidgeWorth Capital Management LLC and Loomis Sayles & Co. L P. Company insiders that have sold Neurocrine Biosciences stock in the last year include Christopher Flint Obrien, Corinne H Nevinny, Dimitri E Grigoriadis, Haig P Bozigian, Kevin Charles Gorman, Kyle Gano, Malcolm Lloyd-Smith, Richard F Pops, Timothy P Coughlin and William H Rastetter.

Who bought Neurocrine Biosciences stock? Who is buying Neurocrine Biosciences stock?

Neurocrine Biosciences' stock was acquired by a variety of institutional investors in the last quarter, including Perceptive Advisors LLC, Franklin Resources Inc., Orbimed Advisors LLC, Janus Capital Management LLC, Alyeska Investment Group L.P., State Street Corp, Marshall Wace LLP and Two Sigma Investments LP.

How do I buy Neurocrine Biosciences stock?

Shares of Neurocrine Biosciences can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Neurocrine Biosciences stock cost?

One share of Neurocrine Biosciences stock can currently be purchased for approximately $42.72.

Neurocrine Biosciences (NASDAQ:NBIX) Chart for Sunday, February, 26, 2017

Institutional Ownership Chart

Institutional Ownership by Quarter for Neurocrine Biosciences (NASDAQ:NBIX)

Earnings History Chart

Earnings by Quarter for Neurocrine Biosciences (NASDAQ:NBIX)

Dividend History Chart

Dividend Payments by Quarter for Neurocrine Biosciences (NASDAQ:NBIX)

Last Updated on 2/26/2017 by Staff